Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : AMERICAN BIOMED, Minimally Invasive Technology (ABMI) -- Ignore unavailable to you. Want to Upgrade?

To: samcat9 who wrote (1449)	7/13/1998 4:24:00 PM
From: Jeffrey L. Henken	Read Replies (3) \| Respond to of 2887

Dr Ahn told me that the bifurcated OmniStent design could be used for virtually the same indications as the AAA Talent system from World Medical. Obviously World Medical will get there first, but I am unaware of anyone else working on a similar product. Who knows, ABMI's designs may be superior. There are plenty of reasons to believe AVEI might be interested in ABMI if for no other reason than to remove the probability of litigation. I know that ABMI does not look like a great stock to own right now. I think it is but it's the marketplace puts a value on anything. When it comes to stocks those values are reflected by a stock's price. When a whole group of stocks like those in the small and microcap area head south a stock like ABMI is simply going to follow. It isn't necessarily a reflection of the company at all. The market for microcaps stocks is stuck in low gear at best after a hard reversal. This weekend I read an article pointing out that this is where investors should be looking for bargains. The larger cap stocks have already recovered from sell offs earlier this year. The small and microcap stocks are oversold. I believe ABMI will pick up because there is plenty of potential here for this company and it's products. All we need is a little change in investor sentiment. No single investor can change the sentiment on a stock but together we can shuck off some of the negativity that is currently being associated with this stock. I mean no one is holding a gun to the head of those who either hold no shares long anymore or don't care about them if they do. I mean it those who are so certain of ABMI's impending doom should simply move on. Life is too short to waste on things you don't believe in. If you ask me ABMI has got several Home Run potential products. They are clearly outlined in the company profile put together by Coffin Communications just last week. But we could argue with the naysayers all day every day whether ABMI was at .01 or 100 so lets just get back to the business of discussing the stock and it's potential from here on out? Anyone think ABMI is a great buy right now? I know I do! Regards, Jeff

To: samcat9 who wrote (1449)	7/13/1998 10:13:00 PM
From: Ray Tarke	Respond to of 2887

ABMI developmental efforts I see some great products in Pipeline! ABMI research and development efforts in interventional cardiology are aimed at increasing the convenience, ease and speed for use of percutaneous transluminal coronary angioplasty ("PTCA") and percutaneous transluminal angioplasty ("PTA") devices (including balloon and atherectomy catheters) while expanding the clinical applications for which PTCA and PTA are appropriate. The development of superior PTCA and PTA catheters requires the resolution of several performance parameters, including catheter profile diameter, trackability (the ability to follow the paths of tortuous arteries) and pushability (the ability to push through tight strictures). Meeting these objectives requires expertise in a number of technical disciplines that the Company must develop and retain internally. The development of the OmniCath, OmniStent and Evert-O- Cath. Research and development efforts for the foreseeable future will be focused on the Company's core technologies which include balloon catheters, OmniCath, OmniStent, blood filter and Evert-O-Cath drug delivery system. ABMI anticipates that research and development expenses will increase as products approach commercial viability and may be funded by increased revenue generated through Cathlab Division sales, from the sale of ancillary technology or through joint development agreements with Strategic Partners. They have great products in the pipeline and some big boys could be looking. I agree with Jeff what a great time to load up. Do your DD call the company check Edgar. Why this stock is a bargain. Regards, R.T * World Com Developmental stage went for $62 million, ABMI could be worth a lot more.